Private Equity 8 Hours

Last updated: April 29, 2026, 5:30 AM ET

European Dealmaking & Sector Moves

Private equity activity saw a major exit confirmation as Advent and Cinven’s €29.4bn sale of the escalator manufacturer TKE provided a rare bright spot in a sluggish exit market, while Blackstone Infrastructure committed capital to Eurowind Energy, a pan-European renewables developer and independent power producer. Elsewhere in Europe, Montagu Private Equity announced plans to acquire Germany’s DQS, a global provider of certification and business assurance services, signaling continued appetite for specialized business services assets. Further consolidation in the security tech space saw Deutsche Beteiligungs AG acquire a stake in Bug Bounty Switzerland, an ethical hacking and Saa S business specializing in intelligent security testing acquiring a stake.

Venture Capital Trends & Geopolitics

Venture capital strategies are adapting to global instability, with firms like Kompas VC deliberately carving out niches focused on startups operating in the physical world rather than purely digital plays, acknowledging that geopolitical turmoil complicates cross-border software investments. This focus on tangible assets contrasts with ongoing regulatory scrutiny in areas like technology chokepoints, which Britain is actively addressing to mitigate national security risks inherent in concentrated supply chains. Meanwhile, ecosystem development remains a focus, evidenced by the Oxford Saïd Entrepreneurship Centre attracting significant investor interest looking to tap into early-stage growth within the academic environment.

Regional Tech Spotlights

Venture capital visibility is being cast across secondary European technology hubs, with reports identifying 16 French startups that venture capitalists are closely monitoring following broader success in established markets. This search for value often leads investors toward emerging centers, as venture firms track the growth of Europe's fastest-rising tier two tech hubs for outsized returns. However, even established biotech ventures face headwinds, as demonstrated by the GV-backed OMass currently engaged in an intellectual property lawsuit, illustrating the persistent legal risks inherent in proprietary technology development.